[go: up one dir, main page]

MX2016011115A - Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1. - Google Patents

Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1.

Info

Publication number
MX2016011115A
MX2016011115A MX2016011115A MX2016011115A MX2016011115A MX 2016011115 A MX2016011115 A MX 2016011115A MX 2016011115 A MX2016011115 A MX 2016011115A MX 2016011115 A MX2016011115 A MX 2016011115A MX 2016011115 A MX2016011115 A MX 2016011115A
Authority
MX
Mexico
Prior art keywords
diabetes
type
immunor
therapy against
against autoimmunity
Prior art date
Application number
MX2016011115A
Other languages
English (en)
Other versions
MX386412B (es
Inventor
Tihamer Orban
Heyam Jalahej
Daubeney Nara
Daubeney Piers
Original Assignee
Tihamer Orban
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tihamer Orban filed Critical Tihamer Orban
Publication of MX2016011115A publication Critical patent/MX2016011115A/es
Publication of MX386412B publication Critical patent/MX386412B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/42—Poisoning, e.g. from bites or stings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

Una terapia para el tratamiento contra la autoinmunidad en diabetes tipo I puede incluir una cantidad terapéuticamente efectiva de dos o más fragmentos superpuestos de preproinsulina y un portador farmacéuticamente aceptable, en donde al menos uno de los fragmentos polipeptídicos es antigénico.
MX2016011115A 2014-02-25 2015-02-20 Composiciòn farmacèutica inmunorreguladora contra autoinmunidad en diabetes tipo i. MX386412B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1403258.5A GB2523399B (en) 2014-02-25 2014-02-25 A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
PCT/GB2015/050493 WO2015128617A1 (en) 2014-02-25 2015-02-20 Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity

Publications (2)

Publication Number Publication Date
MX2016011115A true MX2016011115A (es) 2017-03-20
MX386412B MX386412B (es) 2025-03-18

Family

ID=50482735

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011115A MX386412B (es) 2014-02-25 2015-02-20 Composiciòn farmacèutica inmunorreguladora contra autoinmunidad en diabetes tipo i.
MX2021011189A MX2021011189A (es) 2014-02-25 2016-08-25 Composicion farmaceutica inmunorreguladora contra autoinmunidad en diabetes tipo i.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021011189A MX2021011189A (es) 2014-02-25 2016-08-25 Composicion farmaceutica inmunorreguladora contra autoinmunidad en diabetes tipo i.

Country Status (11)

Country Link
US (3) US11040093B2 (es)
EP (2) EP4134094A1 (es)
JP (1) JP2017520509A (es)
KR (1) KR102412114B1 (es)
CN (1) CN107530404A (es)
AU (3) AU2015221996A1 (es)
CA (1) CA2940726A1 (es)
GB (1) GB2523399B (es)
MX (2) MX386412B (es)
WO (1) WO2015128617A1 (es)
ZA (1) ZA201606836B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113138279A (zh) 2012-06-27 2021-07-20 法姆制药有限责任公司 融合蛋白组合物的应用
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CA3067713A1 (en) * 2017-06-28 2019-01-03 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Method for determining the risk to develop type 1 diabetes
CA3184157A1 (en) 2020-06-26 2021-12-30 Phaim Pharma Ltd Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform
CA3223242A1 (en) * 2021-06-17 2022-12-22 Phaim Pharma Ltd Patient profiling for antigen-specific immunomodulatory therapies
US20240277768A1 (en) * 2021-06-17 2024-08-22 Tihamer Orban Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells
CN116726158A (zh) * 2023-04-24 2023-09-12 中国医学科学院医学生物学研究所 一种多表位1型糖尿病疫苗及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5296729A (en) * 1976-02-05 1977-08-13 Shionogi & Co Ltd Mixed vaccin for cyanomycosis
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DK0606217T4 (da) 1991-06-27 2009-03-30 Bristol Myers Squibb Co CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
CN1157621A (zh) * 1994-07-08 1997-08-20 达特茅斯大学理事会 用于检测和治疗i型糖尿病的胰岛素原肽化合物
US6110746A (en) 1995-06-30 2000-08-29 Yeda Research And Development Co. Ltd. Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
US20030190323A1 (en) 1995-07-05 2003-10-09 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of T cell mediated diseases
US7041634B2 (en) 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
EP0781559B1 (en) 1995-11-30 2007-02-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6797269B2 (en) 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
EP3029062A1 (en) 2000-05-26 2016-06-08 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2413190C (en) 2000-07-03 2009-04-07 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20030045467A1 (en) 2001-01-05 2003-03-06 Tihamer Orban Autoantigen composition
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
ATE454398T1 (de) 2001-10-24 2010-01-15 Univ Cardiff Sperm faktoren sequenzen
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
US7449229B2 (en) * 2002-11-01 2008-11-11 Jeld-Wen, Inc. System and method for making extruded, composite material
WO2007016764A1 (en) 2005-08-06 2007-02-15 Qinghua Wang Composition and method for prevention and treatment of type i diabetes
EP1930415A4 (en) 2005-09-30 2009-05-13 Univ Kyoto DEVELOPMENT OF A SCREENING METHOD FOR A CONNECTABLE COMPOUND FOR IMPROVING THE PRODUCTION OF A REGULATORY T-CELL AND METHOD FOR THE PRODUCTION OF A REGULATORY T-CELL USING AN IMMUNOSUPPRESSIVE MAKROLIDANTIBIOTIC
WO2007127787A2 (en) 2006-04-25 2007-11-08 Joslin Diabetes Center, Inc. Insulin autoantigen-specific regulatory cd4+ t cells
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
GB0712670D0 (en) 2007-06-29 2007-08-08 King S College London Isolated peptides and uses thereof
PT2193142E (pt) 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
US9176122B2 (en) 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CN107441480A (zh) 2010-06-30 2017-12-08 卡姆普根有限公司 多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途
WO2012015903A1 (en) * 2010-07-27 2012-02-02 Bayhill Therapeutics, Inc. Treatment of type i diabetes mellitus (t1dm) in young newly diagnosed patients
US20130316375A1 (en) 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CN113138279A (zh) 2012-06-27 2021-07-20 法姆制药有限责任公司 融合蛋白组合物的应用
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence

Also Published As

Publication number Publication date
CN107530404A (zh) 2018-01-02
JP2017520509A (ja) 2017-07-27
AU2019204371A1 (en) 2019-08-08
KR102412114B1 (ko) 2022-06-21
AU2015221996A1 (en) 2016-10-13
GB2523399B (en) 2019-03-13
EP3110436A1 (en) 2017-01-04
HK1210707A1 (en) 2016-05-06
US20160361397A1 (en) 2016-12-15
GB2523399A (en) 2015-08-26
CA2940726A1 (en) 2015-09-03
NZ724639A (en) 2020-10-30
ZA201606836B (en) 2020-01-29
US20210353727A1 (en) 2021-11-18
US11040093B2 (en) 2021-06-22
MX2021011189A (es) 2021-10-22
US20240316168A1 (en) 2024-09-26
MX386412B (es) 2025-03-18
EP4134094A1 (en) 2023-02-15
KR20170029405A (ko) 2017-03-15
GB201403258D0 (en) 2014-04-09
AU2021232675A1 (en) 2021-10-07
WO2015128617A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
MX2016011115A (es) Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1.
PE20180449A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
UA118558C2 (uk) Пептидна сполука
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
AR101740A1 (es) Terapia de combinación y composiciones
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
CL2015001923A1 (es) Uso de crenolanib para el tratamiento de trastornos proliferativos que tiene flt3 mutado
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
SG11202103097QA (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
MX2016014696A (es) Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
AR099416A1 (es) Terapia combinada para la hipertensión resistente
CL2017002669A1 (es) Un análogo de quinolina trifluoroetil específico para uso en el tratamiento del síndrome de sjögren
CO2022004947A2 (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2018001355A (es) Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones.